Date: 2014-05-21
Type of information: Services contract
Compound: retinal pigment epithelium (RPE) cells to be used in a cell therapy clinical trial
Company: Roslin Cells (UK) Pfizer (USA - NY)
Therapeutic area: Ophtalmological diseases
Type agreement: services
Action mechanism:
Disease: age related macular degeneration
Details: * On May 21, 2014, Roslin Cells announced that it has signed a contract with Pfizer, acting through Neusentis, a research unit of Pfizer based in Cambridge, UK, to support the manufacture of retinal pigment epithelium (RPE) cells to be used in a cell therapy clinical trial. This trial will evaluate the therapy for the treatment of patients suffering from age related macular degeneration (AMD), as part of an ongoing collaboration with The London Project at the Institute of Ophthalmology, UCL. Manufacturing will take place in the company’s GMP Cellular Therapy Manufacturing Facility in Edinburgh, which was licensed by the Medicines Healthcare Products Regulatory Agency (MHRA) in May 2013 for the manufacture of human cell therapy products for clinical trials.
Financial terms:
Latest news:
